RTS,S/AS01 is a safe and moderately efficacious vaccine considered for implementation in endemic Africa. Model predictions of impact and cost-effectiveness of this new intervention could aid in country adoption decisions.; The impact of RTS,S was assessed in 43 countries using an ensemble of models of Plasmodium falciparum epidemiology. Informed by the 32months follow-up data from the phase 3 trial, vaccine effectiveness was evaluated at country levels of malaria parasite prevalence, coverage of control interventions and immunization. Benefits and costs of the program incremental to routine malaria control were evaluated for a four dose schedule: first dose administered at six months, second and third - before 9months, and fourth dose at 27...
SummaryBackgroundThe phase 3 trial of the RTS,S/AS01 malaria vaccine candidate showed modest efficac...
Background. The World Health Organization has recommended pilot implementation of a candidate vaccin...
Background. The World Health Organization has recommended pilot implementation of a candidate vaccin...
AbstractBackgroundRTS,S/AS01 is a safe and moderately efficacious vaccine considered for implementat...
BACKGROUND: RTS,S/AS01 is a safe and moderately efficacious vaccine considered for implementation in...
The phase 3 trial of the RTS,S/AS01 malaria vaccine candidate showed modest efficacy of the vaccine ...
The RTS,S/AS01 malaria vaccine candidate recently completed Phase III trials in 11 African sites. Re...
Background: The RTS,S/AS01 vaccine against P. falciparum malaria infection completed phase 3 trials ...
BackgroundThe RTS,S/AS01 vaccine against Plasmodium falciparum malaria infection completed phase III...
Objectives: To evaluate the relative cost-effectiveness of introducing the RTS,S malaria vaccine in ...
Recent results from the phase 3 trial of RTS,S/AS01 malaria vaccine show that the vaccine induced pa...
Background: The RTS,S/AS01 E malaria vaccine is being assessed in Malawi, Ghana and Kenya as part of...
OBJECTIVES: To evaluate the relative cost-effectiveness of introducing the RTS,S malaria vaccine in ...
Background The RTS,S/AS01 malaria vaccine is currently being evaluated in a cluster-randomized pilot...
Background Following a 30-year development process, RTS,S/AS01E (GSK, Belgium) is the first malar...
SummaryBackgroundThe phase 3 trial of the RTS,S/AS01 malaria vaccine candidate showed modest efficac...
Background. The World Health Organization has recommended pilot implementation of a candidate vaccin...
Background. The World Health Organization has recommended pilot implementation of a candidate vaccin...
AbstractBackgroundRTS,S/AS01 is a safe and moderately efficacious vaccine considered for implementat...
BACKGROUND: RTS,S/AS01 is a safe and moderately efficacious vaccine considered for implementation in...
The phase 3 trial of the RTS,S/AS01 malaria vaccine candidate showed modest efficacy of the vaccine ...
The RTS,S/AS01 malaria vaccine candidate recently completed Phase III trials in 11 African sites. Re...
Background: The RTS,S/AS01 vaccine against P. falciparum malaria infection completed phase 3 trials ...
BackgroundThe RTS,S/AS01 vaccine against Plasmodium falciparum malaria infection completed phase III...
Objectives: To evaluate the relative cost-effectiveness of introducing the RTS,S malaria vaccine in ...
Recent results from the phase 3 trial of RTS,S/AS01 malaria vaccine show that the vaccine induced pa...
Background: The RTS,S/AS01 E malaria vaccine is being assessed in Malawi, Ghana and Kenya as part of...
OBJECTIVES: To evaluate the relative cost-effectiveness of introducing the RTS,S malaria vaccine in ...
Background The RTS,S/AS01 malaria vaccine is currently being evaluated in a cluster-randomized pilot...
Background Following a 30-year development process, RTS,S/AS01E (GSK, Belgium) is the first malar...
SummaryBackgroundThe phase 3 trial of the RTS,S/AS01 malaria vaccine candidate showed modest efficac...
Background. The World Health Organization has recommended pilot implementation of a candidate vaccin...
Background. The World Health Organization has recommended pilot implementation of a candidate vaccin...